Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies
Time: 11:00 am
day: Conference Day 1
Details:
- Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets
- Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data
- Analyzing the development, challenges, and clinical trial results of CAR-T therapies for claudin-targeted treatments, emphasizing construct design, manufacturing hurdles, and strategies for managing associated toxicities
